- Home
- NKTR vs CCIF Comparison
NKTR vs CCIF Comparison
Compare NKTR & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- CCIF
- Stock Information
- Founded
- NKTR 1990
- CCIF 2011
- Country
- NKTR United States
- CCIF United States
- Employees
- NKTR N/A
- CCIF N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- NKTR Health Care
- CCIF Finance
- Exchange
- NKTR Nasdaq
- CCIF Nasdaq
- Market Cap
- NKTR 108.3M
- CCIF 117.0M
- IPO Year
- NKTR 1994
- CCIF N/A
- Fundamental
- Price
- NKTR $22.20
- CCIF $5.29
- Analyst Decision
- NKTR Strong Buy
- CCIF
- Analyst Count
- NKTR 6
- CCIF 0
- Target Price
- NKTR $81.67
- CCIF N/A
- AVG Volume (30 Days)
- NKTR 717.4K
- CCIF 76.9K
- Earning Date
- NKTR 08-07-2025
- CCIF 01-01-0001
- Dividend Yield
- NKTR N/A
- CCIF 25.90%
- EPS Growth
- NKTR N/A
- CCIF N/A
- EPS
- NKTR N/A
- CCIF N/A
- Revenue
- NKTR $87,248,000.00
- CCIF N/A
- Revenue This Year
- NKTR N/A
- CCIF N/A
- Revenue Next Year
- NKTR N/A
- CCIF N/A
- P/E Ratio
- NKTR N/A
- CCIF N/A
- Revenue Growth
- NKTR N/A
- CCIF N/A
- 52 Week Low
- NKTR $6.48
- CCIF $7.43
- 52 Week High
- NKTR $37.38
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- NKTR 54.65
- CCIF 21.87
- Support Level
- NKTR $21.60
- CCIF $5.09
- Resistance Level
- NKTR $23.55
- CCIF $5.59
- Average True Range (ATR)
- NKTR 1.43
- CCIF 0.17
- MACD
- NKTR -0.49
- CCIF -0.04
- Stochastic Oscillator
- NKTR 47.47
- CCIF 18.64
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.